AIM ImmunoTech (AIM) CEO Thomas K. Equels Buys 5,900 Shares

What Happened
Thomas K. Equels, CEO & President (also a Director) of AIM ImmunoTech Inc. (AIM), reported a purchase of 5,900 shares on 2026-09-14 at $0.22 per share, for a total cash outlay of $1,292. The Form 4 marks the transaction with code "P" (purchase) and describes it as an open‑market or private purchase. Purchases by insiders can be read as a mild bullish signal, though this one is small in dollar terms.

Key Details

• Transaction date: 2026-09-14; Filing date (Form 4): 2026-09-15 (timely; within Form 4 reporting window).
• Price and size: 5,900 shares at $0.22 each; total = $1,292.
• Transaction code: P (Purchase) — described as open‑market or private purchase in the filing.
• Shares owned after transaction: Not specified in the summary provided.
• No footnotes, 10b5‑1 plan, or special conditions were disclosed in the information supplied.

Context

• This was a straightforward purchase (not an option exercise, gift, or award).
• The dollar amount is small relative to typical insider trades, so it’s a limited signal; still, purchases by executives are often watched by investors for alignment with company prospects.